FREQ-162

FREQ-162 is an investigational **small molecule** regenerative medicine candidate developed by Frequency Therapeutics for remyelination. It was described as a stem cell stimulant intended to drive progenitor cells in the central nervous system to differentiate into oligodendrocytes, thereby increasing myelin production and potentially restoring damaged neural insulation. The program was positioned primarily for **multiple sclerosis** and potentially other immune system and nervous system disorders involving demyelination, but the specific molecular target has not been publicly defined in the provided context. Based on the available information, the asset appears to have remained preclinical and has been reported as **discontinued**.